$FLYX

FLYWX (FLYX) director receives 46,296 restricted stock units in equity grant

FLYEXCLUSIVE (FLYX) director Frank B. Holding Jr. has received an equity grant of 46,296 restricted stock units (RSUs) of Class A common stock, as reported in a recent Form 4 filing. These RSUs vested immediately upon grant on May 13, 2026, at a stated price of $0.00 per share, increasing his direct holdings to 46,296 shares. The grant represents compensatory equity award rather than a market purchase.

Original reporting
Published May 16, 2026, 4:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 16, 2026, 4:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$FLYX
Neutral
medium confidence
Mentioned
$FLYX · $FLYX
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$FLYXNeutralLow
01

Why it matters

This insider activity may reflect management's confidence but is unlikely to cause significant market movement without additional supporting news.

02

Market read

The news is highly relevant to FLYX shareholders and potential investors interested in insider activity.

03

What to watch

The grant's value at $0.00 suggests it may be more symbolic or compensatory rather than indicative of expected stock appreciation.

Timing: short-term (within days)

Background

The company issued a Form 4 filing indicating an insider received RSUs that vested immediately.

Company-level read

Ticker impact

$FLYXNeutralMedium confidence
Context

The news pertains directly to FLYX (FLYX) as it involves an insider equity grant.

Expected impact

Potential short-term stability or slight upward movement due to insider confidence, but limited immediate market impact.

Evidence & confidence

While insider grants can signal confidence, the grant's value is based on RSUs vested at $0.00, indicating no immediate financial gain or market movement. The impact depends on broader market conditions and investor perception.

$FLYXNeutralMedium confidence
Context

Same as above; the news is highly relevant to FLYX.

Expected impact

Minimal immediate impact; potential for gradual positive sentiment if perceived as a sign of management confidence.

Evidence & confidence

Insider grants are common and do not necessarily predict stock movement; market reaction may be muted unless accompanied by other positive developments.

Market effects

Limited; the news does not indicate sector-wide changes.

Negligible; specific to FLYX and its shareholders.

Negligible; company-specific insider activity.

Counterpoint

Some investors may interpret the grant as a sign of insider confidence, potentially supporting a long-term buy-and-hold strategy.

Key entities

  • FLYEXCLUSIVE Inc.

    The issuer of the RSUs and the subject of the insider activity.

  • Frank B. Holding Jr.

    Director of FLYEXCLUSIVE, recipient of the RSUs.

Related articles

$FLYXMed

FLYEXCLUSIVE INC. (FLYX): Completion of Acquisition or Disposition of Assets

FLYEXCLUSIVE INC. (FLYX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K false 0001843973 0001843973 us-gaap:CommonClassAMember 2026-07-13 2026-07-13 0001843973 2026-07-13 2026-07-13 0001843973 us-gaap:WarrantMember 2026-07-13 2026-07-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ FORM 8-K CURRENT R

$JTAIMedAI 8/10

Jet.AI Closes Transaction with flyExclusive, Advancing Transition to a Pure-Play AI Infrastructure

Jet.AI Inc. (NASDAQ:JTAI) said it closed its merger with flyExclusive, Inc. after stockholder approval and remaining closing conditions. Jet.AI distributed SpinCo shares on July 13, 2026, and SpinCo shares converted into merger consideration. Total consideration was 7,096,115 flyExclusive Class A shares, with 80% issued at closing and 20% held in reserve for 90 days.

$VBIOMed

Valion Bio, Inc.: Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury

Valion Bio (Nasdaq:VBIO) said AFRRI, under a contract with NIAID, is running U.S. government-funded studies of Entolimod for radiation-induced GI injury. A safety study is planned to start this week, followed by a therapeutic study with top-line data expected in early fall. The program aims to assess survival and GI recovery after lethal radiation doses.